The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19

被引：19

作者：

Gozzetti, Alessandro ^{[1
]}

Capochiani, Enrico ^{[2
]}

Bocchia, Monica ^{[1
]}

机构：

[1] Univ Siena, Div Hematol, Siena, Italy

[2] Azienda USL Toscana NordOvest, Ctr Translat Med, Hematol Unit, Livorno, Italy

来源：

LEUKEMIA | 2020年 / 34卷 / 10期

关键词：

D O I：

10.1038/s41375-020-01038-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：2815 / 2816

页数：2

共 50 条

[31] Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19
Tandon, Nitin
Luxami, Vijay
Tandon, Runjhun
Paul, Kamaldeep
MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2022, 22 (21) : 2752 - 2768
[32] Aggressive Merkel Cell Carcinoma After Janus Kinase Inhibitor Ruxolitinib for Polycythemia Vera
Rastrelli, Marco
Ferrazzi, Beatrice
Tropea, Saveria
Costa, Alessandra
Finotto, Silvia
Marino, Dario
Campana, Luca
del Fiore, Paolo
Rossi, Carlo Riccardo
Alaibac, Mauro
IN VIVO, 2019, 33 (05): : 1667 - 1669
[33] Ruxolitinib in COVID-19 Hyperinflammation and Haematologic Malignancies
La Rosee, Felicitas
La Rosee, Paul
ACTA HAEMATOLOGICA, 2021, 144 (03) : 246 - 248
[34] Response to: Ruxolitinib withdrawal due to the COVID-19
Tiziano Barbui
Alessandra Carobbio
Leukemia, 2021, 35 : 1219 - 1219
[35] Response to: Ruxolitinib withdrawal due to the COVID-19
Barbui, Tiziano
Carobbio, Alessandra
LEUKEMIA, 2021, 35 (04) : 1219 - 1219
[36] Janus kinase inhibitor ruxolitinib blocks thymic regeneration after acute thymus injury
Li, Lingling
Shang, Longmei
Gao, Jun
Liu, Cong
Xia, Fan
Xu, Mengdi
Qi, Kunming
Zeng, Lingyu
Pan, Bin
Xu, Kailin
BIOCHEMICAL PHARMACOLOGY, 2020, 171
[37] Differential in vitro interactions of the Janus kinase inhibitor ruxolitinib with human SLC drug transporters
Bruyere, Arnaud
Le Vee, Marc
Jouan, Elodie
Molez, Stephanie
Nies, Anne T.
Fardel, Olivier
XENOBIOTICA, 2021, 51 (04) : 467 - 478
[38] MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naive Myelofibrosis
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Rampal, Raajit K.
Mead, Adam J.
Hobbs, Gabriella
Scandura, Joseph M.
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim C. P.
Hoffman, Ronald
Wondergem, Marielle J.
Salama, Mohamed E.
Colak, Gozde
Cui, Jike
Kiladjian, Jean-Jacques
Vannucchi, Alessandro M.
Verstovsek, Srdan
Curto-Garcia, Natalia
Harrison, Claire
Gupta, Vikas
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (32) : 4993 - +
[39] Efficacy of the Janus kinase 1/2 inhibitor ruxolitinib in the treatment of vasculopathy associated with TMEM173-activating mutations in 3 children
Fremond, Marie-Louise
Rodero, Mathieu Paul
Jeremiah, Nadia
Belot, Alexandre
Jeziorski, Eric
Duffy, Darragh
Bessis, Didier
Cros, Guilhem
Rice, Gillian I.
Charbit, Bruno
Hulin, Anne
Khoudour, Nihel
Caballero, Consuelo Modesto
Bodemer, Christine
Fabre, Monique
Berteloot, Laureline
Le Bourgeois, Muriel
Reix, Philippe
Walzer, Thierry
Moshous, Despina
Blanche, St Ephane
Fischer, Alain
Bader-Meunier, Brigitte
Rieux-Laucat, Frederic
Crow, Yanick Joseph
Neven, Benedicte
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (06) : 1752 - 1755
[40] A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Pemmaraju, Naveen
Kantarjian, Hagop
Kadia, Tapan
Cortes, Jorge
Borthakur, Gautam
Newberry, Kate
Garcia-Manero, Guillermo
Ravandi, Farhad
Jabbour, Elias
Dellasala, Sara
Pierce, Sherry
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (03): : 171 - 176

← 1 2 3 4 5 →